Pomerantz Law Investigates Pharming Group N.V. Amid Investor Concerns

Investigation Announcement by Pomerantz LLP

Pomerantz LLP, a prominent law firm, has initiated an investigation aimed at protecting the interests of investors in Pharming Group N.V. (NASDAQ: PHAR). This inquiry raises critical questions about the company's adherence to securities laws and the integrity of its business practices.

Background on Pharming Group N.V.

Pharming Group N.V. is a biopharmaceutical company known for developing innovative therapies, particularly for rare diseases. The company's flagship product is Joenja® (leniolisib), an oral treatment designed to help children suffering from activated phosphoinositide 3-kinase delta syndrome (APDS), a rare immunodeficiency disorder. Despite its potential, Pharming has recently encountered significant regulatory hurdles that have shaken investor confidence.

On February 1, 2026, Pharming announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding its supplemental New Drug Application (sNDA) for Joenja®. The FDA raised concerns about possible underexposure in pediatric patients with lower body weights, which raises questions about the safety and efficacy of the proposed treatment for vulnerable populations. Moreover, the FDA cited issues related to the analytical methods employed during production batch testing.

The Impact on Investors

The fallout from this announcement was immediate. Pharming’s American Depositary Receipt (ADR) witnessed a drastic decline, plummeting by $3.495, or 17.07%, on February 2, 2026, closing at $16.975 per ADR. This drop signifies a troubling trend for shareholders, who now face mounting uncertainties regarding the company’s future, especially concerning the regulatory oversight of its products.

The Pomerantz investigation aims to ascertain whether Pharming and its executives have participated in any illegal activities that may have contributed to the detrimental performance of its stock. Investors who feel misled or harmed due to the recent developments are encouraged to reach out to Pomerantz for further support. Legal representation may provide a pathway for shareholders to seek restitution for their losses if any wrongdoing is confirmed.

A Legacy of Advocacy

Pomerantz LLP is well-regarded for its dedication to protecting the rights of investors in the realm of corporate litigation. Founded by Abraham L. Pomerantz, the firm has over 85 years of experience in class action lawsuits, especially in areas concerning securities fraud and fiduciary duty breaches. Its reputation as a pioneer in the field assures investors that they are receiving expert legal representation as they navigate these challenging circumstances.

For more information on joining the class action suit or to learn more about this investigation, interested parties can reach out to Danielle Peyton at Pomerantz LLP via email or by phone. As this situation continues to unfold, all eyes will be on Pharming Group N.V. as it attempts to address the FDA’s concerns and regain the trust of its investors.